An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor

Susumu Kobayashi, Hongbin Ji, Yuki Yuza, Matthew Meyerson, Kwok K. Wong, Daniel G. Tenen, Balazs Halmos

Research output: Contribution to journalArticle

214 Citations (Scopus)

Abstract

Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in non-small cell lung cancer specimens from patients responding to anilinoquinazoline EGFR inhibitors. However, clinical resistance to EGFR inhibitor therapy is commonly observed. Previously, we showed that such resistance can be caused by a second mutation of the EGFR gene, leading to a T790M amino acid change in the EGFR tyrosine kinase domain and also found that CL-387,785, a specific and irreversible anilinoquinazoline EGFR inhibitor, was able to overcome this resistance on the biochemical level. Here, we present the successful establishment of a stable Ba/F3 cell line model system for the study of oncogenic EGFR signaling and the functional consequences of the EGFR T790M resistance mutation. We show the ability of gefitinib to induce growth arrest and apoptosis in cells transfected with wild-type or L858R EGFR, whereas the T790M mutation leads to high-level functional resistance against gefitinib and erlotinib. In addition, CL-387,785 is able to overcome resistance caused by the T790M mutation on a functional level, correlating with effective inhibition of downstream signaling pathways. Similar data was also obtained with the use of the gefitinib-resistant H1975 lung cancer cell line. The systems established by us should prove useful for the large-scale screening of alternative EGFR inhibitor compounds against the T790M or other EGFR mutations. These data also support the notion that clinical investigations of compounds similar to CL-387,785 may be useful as a treatment strategy for patients with resistance to EGFR inhibitor therapy caused by the T790M mutation.

Original languageEnglish (US)
Pages (from-to)7096-7101
Number of pages6
JournalCancer Research
Volume65
Issue number16
DOIs
StatePublished - Aug 15 2005
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Mutation
erbB-1 Genes
Cell Line
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Lung Neoplasms
Therapeutics
Apoptosis
Amino Acids
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. / Kobayashi, Susumu; Ji, Hongbin; Yuza, Yuki; Meyerson, Matthew; Wong, Kwok K.; Tenen, Daniel G.; Halmos, Balazs.

In: Cancer Research, Vol. 65, No. 16, 15.08.2005, p. 7096-7101.

Research output: Contribution to journalArticle

Kobayashi, Susumu ; Ji, Hongbin ; Yuza, Yuki ; Meyerson, Matthew ; Wong, Kwok K. ; Tenen, Daniel G. ; Halmos, Balazs. / An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. In: Cancer Research. 2005 ; Vol. 65, No. 16. pp. 7096-7101.
@article{e2995ec29a8547e993280409e4e52db4,
title = "An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor",
abstract = "Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in non-small cell lung cancer specimens from patients responding to anilinoquinazoline EGFR inhibitors. However, clinical resistance to EGFR inhibitor therapy is commonly observed. Previously, we showed that such resistance can be caused by a second mutation of the EGFR gene, leading to a T790M amino acid change in the EGFR tyrosine kinase domain and also found that CL-387,785, a specific and irreversible anilinoquinazoline EGFR inhibitor, was able to overcome this resistance on the biochemical level. Here, we present the successful establishment of a stable Ba/F3 cell line model system for the study of oncogenic EGFR signaling and the functional consequences of the EGFR T790M resistance mutation. We show the ability of gefitinib to induce growth arrest and apoptosis in cells transfected with wild-type or L858R EGFR, whereas the T790M mutation leads to high-level functional resistance against gefitinib and erlotinib. In addition, CL-387,785 is able to overcome resistance caused by the T790M mutation on a functional level, correlating with effective inhibition of downstream signaling pathways. Similar data was also obtained with the use of the gefitinib-resistant H1975 lung cancer cell line. The systems established by us should prove useful for the large-scale screening of alternative EGFR inhibitor compounds against the T790M or other EGFR mutations. These data also support the notion that clinical investigations of compounds similar to CL-387,785 may be useful as a treatment strategy for patients with resistance to EGFR inhibitor therapy caused by the T790M mutation.",
author = "Susumu Kobayashi and Hongbin Ji and Yuki Yuza and Matthew Meyerson and Wong, {Kwok K.} and Tenen, {Daniel G.} and Balazs Halmos",
year = "2005",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-05-1346",
language = "English (US)",
volume = "65",
pages = "7096--7101",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor

AU - Kobayashi, Susumu

AU - Ji, Hongbin

AU - Yuza, Yuki

AU - Meyerson, Matthew

AU - Wong, Kwok K.

AU - Tenen, Daniel G.

AU - Halmos, Balazs

PY - 2005/8/15

Y1 - 2005/8/15

N2 - Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in non-small cell lung cancer specimens from patients responding to anilinoquinazoline EGFR inhibitors. However, clinical resistance to EGFR inhibitor therapy is commonly observed. Previously, we showed that such resistance can be caused by a second mutation of the EGFR gene, leading to a T790M amino acid change in the EGFR tyrosine kinase domain and also found that CL-387,785, a specific and irreversible anilinoquinazoline EGFR inhibitor, was able to overcome this resistance on the biochemical level. Here, we present the successful establishment of a stable Ba/F3 cell line model system for the study of oncogenic EGFR signaling and the functional consequences of the EGFR T790M resistance mutation. We show the ability of gefitinib to induce growth arrest and apoptosis in cells transfected with wild-type or L858R EGFR, whereas the T790M mutation leads to high-level functional resistance against gefitinib and erlotinib. In addition, CL-387,785 is able to overcome resistance caused by the T790M mutation on a functional level, correlating with effective inhibition of downstream signaling pathways. Similar data was also obtained with the use of the gefitinib-resistant H1975 lung cancer cell line. The systems established by us should prove useful for the large-scale screening of alternative EGFR inhibitor compounds against the T790M or other EGFR mutations. These data also support the notion that clinical investigations of compounds similar to CL-387,785 may be useful as a treatment strategy for patients with resistance to EGFR inhibitor therapy caused by the T790M mutation.

AB - Mutations of the epidermal growth factor receptor (EGFR) gene have been identified in non-small cell lung cancer specimens from patients responding to anilinoquinazoline EGFR inhibitors. However, clinical resistance to EGFR inhibitor therapy is commonly observed. Previously, we showed that such resistance can be caused by a second mutation of the EGFR gene, leading to a T790M amino acid change in the EGFR tyrosine kinase domain and also found that CL-387,785, a specific and irreversible anilinoquinazoline EGFR inhibitor, was able to overcome this resistance on the biochemical level. Here, we present the successful establishment of a stable Ba/F3 cell line model system for the study of oncogenic EGFR signaling and the functional consequences of the EGFR T790M resistance mutation. We show the ability of gefitinib to induce growth arrest and apoptosis in cells transfected with wild-type or L858R EGFR, whereas the T790M mutation leads to high-level functional resistance against gefitinib and erlotinib. In addition, CL-387,785 is able to overcome resistance caused by the T790M mutation on a functional level, correlating with effective inhibition of downstream signaling pathways. Similar data was also obtained with the use of the gefitinib-resistant H1975 lung cancer cell line. The systems established by us should prove useful for the large-scale screening of alternative EGFR inhibitor compounds against the T790M or other EGFR mutations. These data also support the notion that clinical investigations of compounds similar to CL-387,785 may be useful as a treatment strategy for patients with resistance to EGFR inhibitor therapy caused by the T790M mutation.

UR - http://www.scopus.com/inward/record.url?scp=23844444080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23844444080&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-1346

DO - 10.1158/0008-5472.CAN-05-1346

M3 - Article

VL - 65

SP - 7096

EP - 7101

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 16

ER -